Investors Purchase High Volume of ASP Isotopes Call Options (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI) was the recipient of some unusual options trading activity on Tuesday. Stock traders bought 17,032 call options on the stock. This is an increase of approximately 76% compared to the average daily volume of 9,673 call options.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a research report on Wednesday, September 17th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $7.75.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, CEO Paul Elliot Mann sold 81,077 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $8.39, for a total value of $680,236.03. Following the transaction, the chief executive officer directly owned 8,084,191 shares in the company, valued at approximately $67,826,362.49. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction on Monday, September 8th. The stock was sold at an average price of $8.53, for a total transaction of $71,976.14. Following the transaction, the chief operating officer owned 1,411,554 shares in the company, valued at $12,040,555.62. This represents a 0.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 245,591 shares of company stock worth $2,139,790 in the last quarter. Company insiders own 21.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASPI. BNP Paribas Financial Markets purchased a new stake in ASP Isotopes during the 4th quarter valued at approximately $34,000. Ameritas Investment Partners Inc. grew its stake in ASP Isotopes by 41.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after acquiring an additional 1,600 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in ASP Isotopes by 84.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company’s stock valued at $44,000 after acquiring an additional 4,299 shares during the last quarter. Millennium Management LLC purchased a new stake in ASP Isotopes in the 4th quarter worth $55,000. Finally, Fortitude Advisory Group L.L.C. purchased a new stake in ASP Isotopes in the 1st quarter worth $64,000. 16.80% of the stock is currently owned by institutional investors.

ASP Isotopes Stock Down 7.1%

ASPI opened at $9.62 on Wednesday. The stock has a market cap of $884.17 million, a price-to-earnings ratio of -15.77 and a beta of 3.35. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. The firm’s fifty day moving average is $9.58 and its 200 day moving average is $7.65. ASP Isotopes has a fifty-two week low of $2.61 and a fifty-two week high of $11.86.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The business had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. On average, sell-side analysts forecast that ASP Isotopes will post -0.24 earnings per share for the current fiscal year.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.